Category Archives: Uncategorized

FDA Approves Expanded Label for Dapagliflozin to Reduce Risk of Cardiovascular Death, Hospitalization from Heart Failure

FDA Approves Expanded Label for Dapagliflozin to Reduce Risk of Cardiovascular Death, Hospitalization from Heart Failure The FDA has approved an expanded label for dapagliflozin (Farxiga; AstraZeneca) to include an indication to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (HF), and urgent HF in adults. blacksalmon – stock.adobe.com The approval for […]

Drugs industry sits down with Government to discuss VPAS successor

Negotiations between the pharmaceutical industry, Government and NHS England around a new branded medicines pricing scheme began yesterday (May 4). The medicines industry was represented by the Association of the British Pharmaceutical Industry (ABPI) at the initial meeting to discuss a successor to the voluntary scheme for branded medicines, pricing and access (VPAS). A joint […]

DEA announces extension for telemedicine prescribing of certain drugs

DEA has said that for now it is extending emergency telehealth policies set during the COVID-19 pandemic, enabling certain health care providers to have greater leeway in prescribing some controlled substances. The DEA decision affects buprenorphine for opioid addiction and stimulants such as amphetamine/dextroamphetamine (Adderall—Teva Pharmaceutics) used to treat ADHD. “We recognize the importance of […]